ProKidney Announces Q3 2025 Financial Outcomes and Key Developments

November 11, 2025 - 01:05

ProKidney has released its financial results for the third quarter of 2025, highlighting significant progress in its clinical studies and regulatory endeavors. The company recently showcased full results from the Phase 2 REGEN-007 study of rilparencel during a late-breaking clinical trial session at the American Society of Nephrology (ASN) Kidney Week 2025. This presentation underscores the promising developments in their research efforts.

As part of their ongoing commitment to advancing kidney disease treatment, ProKidney has successfully enrolled more than half of the patients needed for the Phase 3 REGEN-006 (PROACT 1) accelerated approval analysis, which focuses on the estimated glomerular filtration rate (eGFR) slope. The company anticipates topline results from this study to be available in the second quarter of 2027, marking a critical milestone in their clinical timeline.

Financially, ProKidney concluded the third quarter with a robust position, holding $272 million in cash, cash equivalents, and marketable securities. This financial strength positions the company well for future growth and innovation in the healthcare sector.